Sheba Medical Center to Integrate Elbit Systems Advanced Military Thermal Imaging Technology

Sheba Medical Center, Israel’s largest medical center and a Newsweek top-10 ranked world’s best hospital for the last four years, announced today that is has signed a Memorandum of Understanding (MoU) with Opgal, a subsidiary of Elbit Systems, to utilize advanced thermal imaging technologies previously used for military and security purposes. The integration of the thermal imaging cameras intends to improve the efficiency and efficacy of surgery and treatment in four key areas: heart surgery, diabetic foot treatment, surgical incision infections and respiratory monitoring.

Thermal photography, best known for its role in the world of defense and aerospace, offers significant potential for healthcare. Using thermal cameras, physicians can detect physiological processes based on changes in energy and heat in the body and display these changes on a digital screen. Used in the medical setting, this technology can enable doctors and surgeons to accurately identify the movement of blood vessels and present a clear picture of carbon dioxide being emitted by exhalation.

“The new relationship between medical excellence and excellence in the defense industry is groundbreaking,” said Prof. Eyal Zimlichman, Sheba’s chief innovation and transformation officer, and head of ARC. “The solutions worked on by Elbit and Opgal experts and Sheba doctors are not only significant for Sheba and Israel but will have an international impact. These are global solutions to global problems, and we believe there is great potential here to change the face of medicine on an international level.”

Using these new technological developments, Sheba medical teams will be able to receive previously unavailable new information in real time, for the purpose of formulating increasingly accurate medical diagnoses. The photographed materials will also be analyzed at Sheba using artificial intelligence tools and will enter a computerized database for future use by doctors in decision making.

Sheba Medical Center is leading the digital transformation to advanced digital medicine in Israel and around the world. Sheba, through its innovation arm, ARC (Accelerate, Redesign, Collaborate), is building and maintaining close collaborations and projects with the world’s best hospitals and leading companies in the industry, such as the one with Opgal and Elbit Systems.

“Thermal technology, which until now has helped pilots take off and land, and soldiers on the battlefield identify threats and targets, has the potential to help medical teams worldwide to see the invisible and make more accurate diagnoses,” said Tsachi Israel, CEO of Opgal. “We are the leading experts in our respective fields, working together to innovate in order to save lives and prevent suffering for many patients.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”